UCB S.A. completes €3 billion EMTN Programme
Clients UCB S.A.
Jones Day advised UCB S.A. in connection with the set-up of their €3 billion EMTN Programme for issuance of notes. UCB S.A. is a global biopharmaceutical company, headquartered in Brussels (Belgium) and listed on Euronext Brussels (part of the Bel 20 index). The UCB Group develops and markets human pharmaceutical products for the treatment of severe central nervous system (CNS) and immunology disorders.